FierceBiotech 19 mar 2026 Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech 19 mar 2026 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
Endpoints News 19 mar 2026 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
BioPharma Dive 12 mar 2026 Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Endpoints News 12 mar 2026 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News 11 mar 2026 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Pharmaron 11 mar 2026 Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Endpoints News 6 mar 2026 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president
Endpoints News 24 feb 2026 Novo Nordisk’s triple-G is competitive with Lilly in obesity, but likely to be second to market
BioPharma Dive 23 feb 2026 Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Endpoints News 23 feb 2026 Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial